CX Institutional’s GSK GSK Stock Holding History

CX Institutional’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$46K	Buy	882 +100	+13%	+$5.29K	﹤0.01%	996
2026 Q1	$43K	Sell	782 -15	-2%	-$813	﹤0.01%	997
2025 Q4	$39K	Buy	797 +21	+3%	+$979	﹤0.01%	1009
2025 Q3	$33K	Sell	776 -1,217	-61%	-$47.5K	﹤0.01%	1010
2025 Q2	$77K	Buy	1,993 +818	+70%	+$31.3K	﹤0.01%	799
2025 Q1	$46K	Buy	+1,175	New	+$43K	﹤0.01%	845
2022 Q3	–	Sell	-582	Closed	-$32K	–	747
2022 Q2	$32K	Buy	+582	New	+$32.1K	﹤0.01%	759
2020 Q2	–	Sell	-42	Closed	-$2K	–	859
2020 Q1	$2K	Buy	+42	New	+$2.24K	﹤0.01%	670
2019 Q2	–	Sell	-1,334	Closed	-$70K	–	967
2019 Q1	$70K	Buy	+1,334	New	+$66.7K	0.01%	305

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

CX Institutional's GSK Position: Q2 2026 in Review

CX Institutional increased its GSK (GSK) stake by 13% in Q2 2026, buying an estimated $5.29K and bringing the position to 882 shares worth $46K. The position accounts for ﹤0.01% of the portfolio, ranked #996.

CX Institutional first reported a position in GSK in Q1 2019 and has held it in 9 quarters since. The position peaked at $77K in Q2 2025. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

CX Institutional held 882 shares of GSK worth $46K as of Q2 2026.
CX Institutional bought 100 GSK shares in Q2 2026, an estimated $5.29K.
GSK made up ﹤0.01% of CX Institutional's portfolio in Q2 2026, its #996 holding.
CX Institutional first reported a position in GSK in Q1 2019 and has held it in 9 quarters since.
CX Institutional's GSK position peaked at $77K in Q2 2025.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.